Could a diabetes drug stop AFib from coming back?

NCT ID NCT06528262

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether enavogliflozin, a drug originally for diabetes, can prevent atrial fibrillation (AF) from returning after a catheter ablation procedure in people with AF and heart failure. About 390 adults will receive either the drug or a placebo daily for a year. The main goal is to see if the drug reduces AF recurrence between 3 months and 1 year after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enavogliflozin (a type of SGLT2 inhibitor drug, originally used for diabetes)
What this could lead to: If it works, this could provide a new way to prevent atrial fibrillation from coming back after a common heart procedure, especially for people with heart failure.
What could go wrong: This is a Phase 4 trial, but it is still relatively small (390 people) and only tests one drug. Previous studies were mostly in people with diabetes, so results may not apply to everyone. The drug may not reduce recurrence significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION

Contacts and locations

Locations

Severance Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.